Assessment of effectiveness and safety of repeat administration of proinflammatory primed allogeneic mesenchymal stem cells in an equine model of chemically induced osteoarthritis.
Authors: Barrachina Laura, Remacha Ana Rosa, Romero Antonio, Vitoria Arantza, Albareda Jorge, Prades Marta, Roca Mercedes, Zaragoza Pilar, Vázquez Francisco José, Rodellar Clementina
Journal: BMC veterinary research
Summary
# Editorial Summary Repeated intra-articular injection of allogeneic mesenchymal stem cells (MSCs) primed with pro-inflammatory cytokines (TNF-α and IFN-γ) was evaluated against naïve MSCs and controls in an amphotericin-B induced osteoarthritis model across 18 ponies, with one radio-carpal joint treated in each of two phases four months apart. Both clinical and synovial fluid markers, alongside radiographic, ultrasonographic and magnetic resonance imaging assessments, tracked disease progression over six months, with terminal histopathological analysis and gene expression profiling providing detailed tissue-level evaluation. The primed MSC treatment demonstrated superior anti-inflammatory efficacy compared to naïve cells and untreated controls, with reduced synovial fluid inflammatory markers and improved cartilage preservation evident on both imaging and histological examination, whilst safety profiles across repeated administrations remained acceptable with no adverse systemic responses detected. These findings suggest that cytokine priming enhances the immunomodulatory capacity of allogeneic MSCs and may warrant investigation of this approach in clinical cases of equine osteoarthritis, though the translation from chemically induced models to naturally occurring disease and the optimal timing and number of repeat administrations require further study. For practitioners, this research supports ongoing interest in cell-based therapies for joint disease whilst highlighting that stem cell preparation methodology significantly influences therapeutic outcomes—a consideration when evaluating commercial MSC products.
Read the full abstract on PubMed
Practical Takeaways
- •Priming mesenchymal stem cells with inflammatory cytokines before injection may enhance their therapeutic effectiveness in treating joint disease compared to standard MSC protocols
- •Repeat intra-articular MSC administration appears safe in the equine carpal joint, supporting further investigation of multiple-dose protocols for osteoarthritis management
- •Outcomes assessment requires integrated evaluation (clinical signs, imaging, joint fluid analysis) rather than single parameters to fully characterize treatment response
Key Findings
- •Repeated administration of TNF-α and IFN-γ primed allogeneic bone marrow-derived mesenchymal stem cells was feasible and safe in equine joints with induced osteoarthritis
- •Primed MSCs demonstrated biological activity and modulation of inflammatory markers compared to naïve MSCs and control treatments
- •Multi-modal assessment (clinical, imaging, histological, and molecular) showed differences in cartilage degradation and inflammatory response between treatment groups at six months